{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T18:10:17Z","timestamp":1788977417338,"version":"build-2803163510"},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":62,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health\u2014Ricerca Corrente"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>HER2 amplification identifies a subgroup of colorectal cancer with poorer prognosis and resistance to anti-EGFR therapy. We conducted a systematic review and a meta-analysis of available data on anti-HER2 treatments (HER2Tx) in mCRC patients (pts).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A systematic literature search was performed, encompassing phase II\/III clinical trials (CTs) investigating HER2Tx in HER2-overexpressed mCRC. CTs reporting HER2Tx plus chemotherapy were excluded. Primary endpoints were objective response rate (ORR) and disease control rate (DCR). Fixed and random-effect models were applied according to heterogeneity assessed through I 2 statistics. Progression-free survival (PFS) and overall survival (OS) were compared descriptively and pooled using the weighted median of medians (WM) with approximated 95% CIs. Subgroup analyses by HER2Tx were carried out.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The analysis included 10 CTs evaluating Trastuzumab-Pertuzumab (T\u2009+\u2009P, 5 CTs,), Trastuzumab Deruxtecan (T-DXd, 2 CTs), Trastuzumab-Lapatinib (T\u2009+\u2009L, 1 CT), Pertuzumab-TDM1 (P+TDM1, 1 CT), and Trastuzumab-Tucatinib (T-Tu, 1 CT), for a total of 467 pts. The pooled ORR was 33.7% (29.6%-38.1%), and the pooled DCR was 68.5% (58.1%-77.4%). The WM OS was 13.4\u2009months (10-24.1) and WM PFS was 5.5\u2009months (4.1-6.9). The T-DX and T-Tu groups showed higher ORR and DCR (38% and 39% respectively, 85.1% and 73.2% respectively) compared to the T\u2009+\u2009P group (ORR, 30%; DCR, 52.6%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>HER2Tx demonstrated efficacy in pretreated CRC pts, exhibiting good DCR and ORR alongside promising PFS and OS. T-DXd and T-Tu appear to outperform T\u2009+\u2009P; however, further studies are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag224","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T11:57:12Z","timestamp":1783511832000},"source":"Crossref","is-referenced-by-count":0,"title":["Anti-Human Epidermal Growth Factor Receptor 2 therapies in metastatic colorectal cancer: a systematic review and meta-analysis"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3144-4672","authenticated-orcid":false,"given":"Simone","family":"Rota","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8918-1201","authenticated-orcid":false,"given":"Paola","family":"Di Nardo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Zottarelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiola","family":"Giudici","sequence":"additional","affiliation":[{"name":"Unit of Cancer Epidemiology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Vida","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Zilli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"de Scordilli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Foltran","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Guardascione","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0548-7092","authenticated-orcid":false,"given":"Elena","family":"Ongaro","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Puglisi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, CRO di Aviano\u2014National Cancer Institute, IRCCS , Aviano, 33081,","place":["Italy"]},{"name":"Department of Medicine (DMED), University of Udine , Udine, 33100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"key":"2026090913531029200_oyag224-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2026090913531029200_oyag224-B2","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"key":"2026090913531029200_oyag224-B3","author":"Aiom","year":"2024"},{"key":"2026090913531029200_oyag224-B4","first-page":"6","article-title":"Colon cancer, version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Benson","year":"2024","journal-title":"J Natl Compreh Cancer Netw"},{"key":"2026090913531029200_oyag224-B5","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","article-title":"Pembrolizumab in microsatellite-instability\u2013high advanced colorectal cancer","volume":"383","author":"Andr\u00e9","year":"2020","journal-title":"N Engl J Med"},{"key":"2026090913531029200_oyag224-B6","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.3390\/cancers14205160","article-title":"Emerging role of ERBB2 in targeted therapy for metastatic colorectal cancer: signaling pathways to therapeutic strategies","volume":"14","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026090913531029200_oyag224-B7","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"2026090913531029200_oyag224-B8","doi-asserted-by":"crossref","first-page":"102363","DOI":"10.1016\/j.ctrv.2022.102363","article-title":"HER2 targeted therapy in colorectal cancer: new horizons","volume":"105","author":"Suwaidan","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"2026090913531029200_oyag224-B9","doi-asserted-by":"crossref","first-page":"188605","DOI":"10.1016\/j.bbcan.2021.188605","article-title":"Clinicopathologic features and treatment advances in cancers with HER2 alterations","volume":"1876","author":"Cen","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"2026090913531029200_oyag224-B10","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"key":"2026090913531029200_oyag224-B11","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1093\/annonc\/mdu275","article-title":"Distal and proximal Colon cancers differ in terms of molecular, pathological, and clinical features","volume":"25","author":"Missiaglia","year":"2014","journal-title":"Ann Oncol"},{"key":"2026090913531029200_oyag224-B12","doi-asserted-by":"crossref","first-page":"e0151865","DOI":"10.1371\/journal.pone.0151865","article-title":"BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis","volume":"11","author":"Nam","year":"2016","journal-title":"PLoS One"},{"key":"2026090913531029200_oyag224-B13","doi-asserted-by":"crossref","first-page":"86356","DOI":"10.18632\/oncotarget.21169","article-title":"Comparative molecular analyses of left-sided colon, right-sided colon, and rectal cancers","volume":"8","author":"Salem","year":"2017","journal-title":"Oncotarget"},{"key":"2026090913531029200_oyag224-B14","doi-asserted-by":"crossref","first-page":"102488","DOI":"10.1016\/j.ctrv.2022.102488","article-title":"The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review","volume":"112","author":"Vaghi","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"2026090913531029200_oyag224-B15","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1158\/2159-8290.CD-14-1211","article-title":"HER2 activating mutations are targets for colorectal cancer treatment","volume":"5","author":"Kavuri","year":"2015","journal-title":"Cancer Discov"},{"key":"2026090913531029200_oyag224-B16","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1634\/theoncologist.2018-0785","article-title":"HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer","volume":"24","author":"Sartore-Bianchi","year":"2019","journal-title":"Oncologist"},{"key":"2026090913531029200_oyag224-B17","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"key":"2026090913531029200_oyag224-B18","doi-asserted-by":"crossref","first-page":"e000911","DOI":"10.1136\/esmoopen-2020-000911","article-title":"Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial","volume":"5","author":"Sartore-Bianchi","year":"2020","journal-title":"ESMO Open"},{"key":"2026090913531029200_oyag224-B19","doi-asserted-by":"crossref","first-page":"v199","DOI":"10.1093\/annonc\/mdz246.004","article-title":"TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (patients) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): a GOZILA sub-study","volume":"30","author":"Nakamura","year":"2019","journal-title":"Ann. Oncol"},{"key":"2026090913531029200_oyag224-B20","doi-asserted-by":"publisher","first-page":"e2200306","DOI":"10.1200\/PO.22.00306","article-title":"Pertuzumab plus trastuzumab in patients with colorectal cancer with ERBB2 amplification or ERBB2\/3 mutations: results from the TAPUR study","volume":"6","author":"Gupta","year":"2022","journal-title":"JCO Precis Oncol"},{"key":"2026090913531029200_oyag224-B21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"key":"2026090913531029200_oyag224-B22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S1470-2045(23)00150-X","article-title":"Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study","volume":"24","author":"Strickler","year":"2023","journal-title":"Lancet Oncol"},{"key":"2026090913531029200_oyag224-B23","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"key":"2026090913531029200_oyag224-B24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"key":"2026090913531029200_oyag224-B25","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1002\/sim.8013","article-title":"One-sample aggregate data meta-analysis of medians","volume":"38","author":"McGrath","year":"2019","journal-title":"Stat Med"},{"key":"2026090913531029200_oyag224-B26","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1200\/jco.2012.30.15_suppl.3502","article-title":"Phase III CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC)","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"JCO"},{"key":"2026090913531029200_oyag224-B27","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1056\/NEJMoa2214963","article-title":"Trifluridine\u2013tipiracil and bevacizumab in refractory metastatic colorectal cancer","volume":"388","author":"Prager","year":"2023","journal-title":"N Engl J Med"},{"key":"2026090913531029200_oyag224-B28","doi-asserted-by":"crossref","first-page":"TPS3631","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS3631","article-title":"MOUNTAINEER-03: phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer","volume":"41","author":"Bekaii-Saab","year":"2023","journal-title":"JCO"},{"key":"2026090913531029200_oyag224-B29","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1038\/modpathol.2015.98","article-title":"Assessment of a HER2 scoring system for colorectal cancer: results from a validation study","volume":"28","author":"Valtorta","year":"2015","journal-title":"Mod Pathol"},{"key":"2026090913531029200_oyag224-B30","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/oncolo\/oyad200","article-title":"Impact of anti-EGFR therapies on HER2-positive metastatic colorectal cancer: a systematic literature review and meta-analysis of clinical outcomes","volume":"28","author":"Bekaii-Saab","year":"2023","journal-title":"Oncologist"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag224\/68741446\/oyag224.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag224\/71011956\/oyag224.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag224\/71011956\/oyag224.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:53:21Z","timestamp":1788976401000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag224\/8729398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":30,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag224","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,7,9]]},"article-number":"oyag224"}}